MorphoSys AG (MOR)
17.89
+0.02
(+0.11%)
USD |
NASDAQ |
May 03, 16:00
17.90
+0.01
(+0.06%)
After-Hours: 20:00
MorphoSys SG&A Expense (Quarterly): -9.867M for Dec. 31, 2023
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | -9.867M |
September 30, 2023 | 38.00M |
June 30, 2023 | 42.53M |
March 31, 2023 | 29.82M |
December 31, 2022 | -22.27M |
September 30, 2022 | 39.39M |
June 30, 2022 | 38.76M |
March 31, 2022 | 40.94M |
December 31, 2021 | -51.36M |
September 30, 2021 | 61.08M |
June 30, 2021 | 71.05M |
March 31, 2021 | 46.30M |
December 31, 2020 | -28.80M |
September 30, 2020 | 53.94M |
June 30, 2020 | 47.47M |
March 31, 2020 | 25.33M |
December 31, 2019 | 15.41M |
September 30, 2019 | 14.94M |
June 30, 2019 | 12.00M |
March 31, 2019 | 8.626M |
December 31, 2018 | 11.70M |
September 30, 2018 | 7.462M |
June 30, 2018 | 8.266M |
March 31, 2018 | 5.797M |
December 31, 2017 | 8.414M |
Date | Value |
---|---|
September 30, 2017 | 5.265M |
June 30, 2017 | 5.434M |
March 31, 2017 | 4.231M |
December 31, 2016 | 6.002M |
September 30, 2016 | 3.813M |
June 30, 2016 | 4.144M |
March 31, 2016 | 3.562M |
December 31, 2015 | -0.1356M |
September 30, 2015 | 3.953M |
June 30, 2015 | 4.434M |
March 31, 2015 | 3.369M |
December 31, 2014 | -0.8249M |
September 30, 2014 | 4.775M |
June 30, 2014 | 4.706M |
March 31, 2014 | 4.542M |
December 31, 2013 | -2.635M |
September 30, 2013 | 6.392M |
June 30, 2013 | 6.335M |
March 31, 2013 | 4.718M |
December 31, 2012 | -1.467M |
September 30, 2012 | 3.767M |
June 30, 2012 | 3.943M |
March 31, 2012 | 3.313M |
December 31, 2011 | -2.487M |
September 30, 2011 | 7.466M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
-51.36M
Minimum
Dec 2021
71.05M
Maximum
Jun 2021
24.46M
Average
38.00M
Median
Sep 2023
SG&A Expense (Quarterly) Benchmarks
Incyte Corp | 300.30M |
Novartis AG | 2.84B |
Immatics NV | 11.17M |
Affimed NV | 6.642M |
InflaRx NV | 4.562M |